Results 121 to 130 of about 174,156 (175)

Increased Phosphorylation of Intracellular Signaling Molecules Indicates Continuous Activation of Human Autoreactive B-Cells. [PDF]

Eur J Immunol
Kroos S, Blomberg NJ, Kwekkeboom JC, Hendriks RW, Corneth OBJ, Toes REM, Scherer HU.   +6 more
europepmc   +1 more source

COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale. [PDF]

Nat Commun
Lin H, Yang B, Ding L, Yang YY, Holt MV, Jung SY, Zhang B, Wang MC, Wang J.   +8 more
europepmc   +1 more source

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. [PDF]

Blood Adv
Brown JR, Li J, Eichhorst BF, Lamanna N, O'Brien SM, Tam CS, Qiu L, Huang R, Shi Y, Idoine A, Salmi T, Cohen AC, Shadman M.   +12 more
europepmc   +1 more source

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). [PDF]

Cancer Chemother Pharmacol
Ouerdani A, Valenzuela B, Treijtel N, Haddish-Berhane N, Desphande S, Srinivasan S, Smith E, Perez Ruixo JJ.   +7 more
europepmc   +1 more source

A fresh look at covalent BTK inhibitor resistance.

Blood
Roeker LE.
europepmc   +1 more source

Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase. [PDF]

J Virol
Niu K, Wang X, Jiang Q, Liu K, Xie S, Song B, Wu W, Li X, Peng C.   +8 more
europepmc   +1 more source

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. [PDF]

Blood Adv
Heyman BM, Opat SS, Wahlin BE, Dimopoulos MC, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen A, Matous JV.   +16 more
europepmc   +1 more source

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. [PDF]

Cancer Med
Lee BJ, Liu J, Griffin SP, Doh J, Ciurea SO, Kongtim P, Brem EA.   +6 more
europepmc   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy. [PDF]

J Pathol
László T, Pinczés LI, Bátai B, Varga L, Timár B, Gulyás A, Tárkányi I, Plander M, Nagy Z, Rajnics P, Egyed M, Molnár Z, Rottek J, Masszi A, Tamáska P, Szász R, Illés Á, Alpár D, Magyari F, Bödör C.   +19 more
europepmc   +1 more source